4 documents found, page 1 of 1
Perspectives on the Implementation of Mental Health Apps on Clinical Interventi...
Neto, Daniel; Spínola, Carla; Pinto, H Sofia; Gago, JoaquimN/a.; N/a.
Translation and Validation of the European Portuguese Version of the Quality of...
Brito-Santana, Leonor; Passos, João; Jeremias, Daniela; Azevedo, Filipe; Neto, Daniel; Salgado, DuarteIntroduction: The INF1-QoL questionnaire is an essential tool for assessing patients’ perceptions of their illness and its impact on their daily lives. This study aimed to obtain and validate the European Portuguese version of this questionnaire. Methods: The English version of INF1-QoL was translated using the “forward-backward” procedure. The questionnaire was administered to 78 adult patients with neurofibro...
Translation and Validation of the European Portuguese Version of the Quality of...
Brito-Santana, Leonor; Passos, João; Jeremias, Daniela; Azevedo, Filipe; Neto, Daniel; Salgado, DuartePublisher Copyright: © Author(s) (or their employer(s)) and Sinapse 2024.; Introduction: The INF1-QoL questionnaire is an essential tool for assessing pa-tients’ perceptions of their illness and its impact on their daily lives. This study aimed to obtain and validate the European Portuguese version of this questionnaire. Methods: The English version of INF1-QoL was translated using the “forward-backward” proced...
Lurasidone: Ten Years Treating Adults with Bipolar Depression
Albuquerque, Margarida; Facucho-Oliveira, João; Esteves-Sousa, Daniel; Moura, Nuno; Neto, Daniel; Cintra, PedroLurasidone is an atypical antipsychotic approved in 2010 in Canada and in the USA for the treatment of adults with schizophrenia or bipolar type I disorder. In 2014 it was approved in the European Union for the treatment of patients with 13 years‑old or older, with schizophrenia. Lurasidone is a benzisothiazole derivative with a binding profile that makes it an antidepressant candidate with a low metabolic impa...